Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity

Targeted therapeutics that can differentiate between normal and malignant tumor cells represent the ideal standard for the development of a successful anti-cancer strategy. The Sialyl-Thomsen-nouveau antigen (STn or Sialyl-Tn, also known as CD175s) is rarely seen in normal adult tissues, but it is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Prendergast, Jillian M., Galvao da Silva, Ana Paula, Eavarone, David A., Ghaderi, Darius, Zhang, Mai, Brady, Dane, Wicks, Joan, DeSander, Julie, Behrens, Jeff, Rueda, Bo R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419082/
https://www.ncbi.nlm.nih.gov/pubmed/28281872
http://dx.doi.org/10.1080/19420862.2017.1290752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419082/
https://www.ncbi.nlm.nih.gov/pubmed/28281872
http://dx.doi.org/10.1080/19420862.2017.1290752

Ejemplares similares